Cardiogenic shock

Critical Care Clinics

Volumn 17, Issue 2, 2001, Pages 391-410

  Hollenberg, Steven M ^b  

^a Department of Internal Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ANGIOPLASTY; AORTA BALLOON; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CORONARY ARTERY SURGERY; CORONARY STENT; HEART CATHETERIZATION; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART OUTPUT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0034952206     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(05)70174-3     Document Type: Article

References (71)

1. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
2. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: In-hospital and long-term survival
3. Contribution of myocyte apoptosis to myocardial infarction?
4. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: A theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock
5. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease
6. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study
7. One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: Results from the GUSTO-I Trial
8. Basic and clinical aspects of myocardial stunning
9. Emergency cardiac procedures in patients in cardiogenic shock due to complications of coronary artery disease
10. The hibernating myocardium: Implications for management of congestive heart failure
11. Effect of reperfusion on biventricular function and survival after right ventricular infarction
12. Cardiogenic shock
13. Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy
14. Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction
15. Intraaortic balloon counterpulsation with and without reperfusion for myocardial infarction shock
16. Use of a monoclonal antibody directed against the platelet glyco-protein IIb/IIIa receptor in high-risk coronary angioplasty
17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
18. A randomized trial of intravenous nitroglycerin in patients with acute myocardial infarction
19. Results of a randomized prospective trial of intra-aortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction
20. Medical therapy of acute myocardial infarction by application of hemodynamic subsets
21. Thrombolytic therapy in cardiogenic shock: Effect of increased aortic pressure and rapid tPA administration
22. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina: Direct evidence for myocardial stunning in humans
23. Cardiogenic shock after acute myocardial infarction: Incidence and mortality from a community-wide perspective, 1975 to 1988
24. Temporal trends in cardiogenic shock complicating acute myocardial infarction
25. Aggressive intervention for myocardial infarction: Angioplasty, stents, and intra-aortic balloon pumping
26. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
27. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
28. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
29. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
30. The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors
31. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery
32. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction
33. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: Results of an International Registry
34. Early revascularization in acute myocardial infarction complicated by cardiogenic shock
35. Practice parameters for hemodynamic support of sepsis in adult patients
36. Pulmonary artery catheters in cardiovascular disease
37. Cardiogenic shock
38. Reversible causes of severe myocardial dysfunction
39. Shock
40. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience: The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
41. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
42. Acute myocardial infarction treated with intracoronary streptokinase: A report of the Society for Cardiac Angiography
43. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty
44. Valvular emergencies
45. Early repair of postinfarction ventricular septal rupture
46. Right ventricular infarction
47. Thrombolysis plus aortic counterpulsation: Improved survival in patients who present to community hospitals with cardiogenic shock
48. Multicenter registry of angioplasty therapy of cardiogenic shock: Initial and long-term survival
49. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: Incidence, risk factors, and outcome
50. Pathogenesis and management of acute heart failure and cardiogenic shock: Role of inotropic therapy
51. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction
52. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: Results of a randomized trial
53. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart
54. Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure
55. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator
56. Ischemic left ventricular free wall rupture: Prediction, diagnosis, and treatment
57. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock
58. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
59. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy
60. Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarctions complicated by cardiogenic shock
61. A comparison of balloon-expandablestent implantation with balloon angioplasty in patients with coronary artery disease
62. Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital
63. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: The Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial
64. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30-day results of the PAMI stent pilot trial
65. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings
66. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH
67. Direct percutaneous transluminal coronary angioplasty in acute myocardial infarction: Predictors of short-term outcome and the impact of coronary stenting: Study Group of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK)
68. Usefulness of coronary stenting for cardiogenic shock
69. Severe diffuse hypokinesis of the remote myocardium: The main cause of cardiogenic shock? An echocardiographic study of 75 patients with extremely large myocardial infarctions
70. Hibernating myocardium
71. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction